Empowered Patient Podcast Developing Psychedelic Therapy for Rapid Improvement of Postpartum Depression with Greg Mayes Reunion Neuroscience
Greg Mayes, President and CEO of Reunion Neuroscience, is developing a psychedelic therapy for the treatment of postpartum depression. This serious acute, non-chronic mental health condition affects an estimated 20% of women after giving birth. A phase two trial is underway to evaluate how RE-104, a rapid-acting psilocybin-like novel molecule, can help women with moderate to severe postpartum depression get faster relief compared to existing treatments.
Greg explains, "The course of our psychedelic administration is significant because we believe it can be shorter in time period than other psilocybin-like treatments. In our case, we were able to establish it as 3.7 hours. Because it's a psychedelic and it is for an acute and non-chronic indication, we believe that women who take our product will see a rapid uptake and potentially day of administration benefit of the psychedelic therapy. Our phase two study is called the RECONNECT study because it's named for women reconnecting with themselves, their families, their children, and the world around them."
"Postpartum depression is considered to be a subset depressive of major depressive disorder, major depressive order that's not put into remission after two treatments becomes treatment-resistant depression. There's also generalized anxiety disorder. We believe that RE104 and our lead product have a lot of legs to potentially go in this area. But as the CEO of the company, we want to stay focused. We know what we need to do first and foremost is we need to get our RECONNECT phase two proof of concept study and women with moderate to severe postpartum depression recruited. And we need to show that we can work there. Once we show that, we'll pivot to other indications. One is adjustment disorder in patients with cancer and with other major medical illnesses like Parkinson's disease, ALS, MS, or pulmonary fibrosis."
#ReunionNeuro #PostPartumDepression #PPD #Psychedelics #Mothers #MentalHealth #Depression #RECONNECTStudy